- Home
- AYTU vs MBIO Comparison
AYTU vs MBIO Comparison
Compare AYTU & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- MBIO
- Stock Information
- Founded
- AYTU N/A
- MBIO 2015
- Country
- AYTU United States
- MBIO United States
- Employees
- AYTU N/A
- MBIO N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- MBIO Health Care
- Exchange
- AYTU Nasdaq
- MBIO Nasdaq
- Market Cap
- AYTU 9.8M
- MBIO 9.1M
- IPO Year
- AYTU N/A
- MBIO N/A
- Fundamental
- Price
- AYTU $1.38
- MBIO $0.17
- Analyst Decision
- AYTU
- MBIO Strong Buy
- Analyst Count
- AYTU 0
- MBIO 1
- Target Price
- AYTU N/A
- MBIO $2.00
- AVG Volume (30 Days)
- AYTU 37.2K
- MBIO 669.7K
- Earning Date
- AYTU 02-12-2025
- MBIO 11-08-2024
- Dividend Yield
- AYTU N/A
- MBIO N/A
- EPS Growth
- AYTU N/A
- MBIO N/A
- EPS
- AYTU N/A
- MBIO N/A
- Revenue
- AYTU $79,759,000.00
- MBIO N/A
- Revenue This Year
- AYTU N/A
- MBIO N/A
- Revenue Next Year
- AYTU N/A
- MBIO N/A
- P/E Ratio
- AYTU N/A
- MBIO N/A
- Revenue Growth
- AYTU N/A
- MBIO N/A
- 52 Week Low
- AYTU $1.30
- MBIO $0.13
- 52 Week High
- AYTU $3.45
- MBIO $1.53
- Technical
- Relative Strength Index (RSI)
- AYTU 33.90
- MBIO 33.19
- Support Level
- AYTU $1.30
- MBIO $0.15
- Resistance Level
- AYTU $1.47
- MBIO $0.21
- Average True Range (ATR)
- AYTU 0.12
- MBIO 0.02
- MACD
- AYTU -0.01
- MBIO -0.00
- Stochastic Oscillator
- AYTU 17.78
- MBIO 25.56
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.